Showing 2,301 - 2,320 results of 3,304 for search '"clinical trial"', query time: 0.11s Refine Results
  1. 2301

    Clinical and Pathological Characteristics of Autoimmune Hepatitis with Acute Presentation by Yi Shen, Changli Lu, Ruoting Men, Jianping Liu, Tinghong Ye, Li Yang

    Published 2018-01-01
    “…This study was registered at ClinicalTrials.gov (identifier: NCT02994537).…”
    Get full text
    Article
  2. 2302

    Two Approaches to Cognitive Evaluation: Assessing the Strengths and Limitations of GPCOG and ACE-III by Magdalena Mąka, Dominik Sikora, Piotr Oleksy, Adam Zając, Karol Zieliński, Łukasz Papież, Ewa Góralczyk, Jakub Kamiński, Bartosz Buczkowski, Dagmara Wochnik

    Published 2025-02-01
    “…Materials and Methods : A review of 37 peer-reviewed studies, including clinical trials and validation research, was conducted using databases like PubMed and Google Scholar. …”
    Get full text
    Article
  3. 2303

    Sulodexide Protects Renal Tubular Epithelial Cells from Oxidative Stress-Induced Injury via Upregulating Klotho Expression at an Early Stage of Diabetic Kidney Disease by Yu Ning Liu, Jingwei Zhou, Tingting Li, Jing Wu, Shu Hua Xie, Hua-feng Liu, Zhangsuo Liu, Tae Sun Park, Yaoxian Wang, Wei Jing Liu

    Published 2017-01-01
    “…The hypoalbuminuric effect of sulodexide (SDX) on diabetic kidney disease (DKD) was suggested by some clinical trials but was denied by the Collaborative Study Group. …”
    Get full text
    Article
  4. 2304

    Canadian Expert Panel Recommendations on the Management of CNS Symptoms Related to Efavirenz by M John Gill, Anita Rachlis, Sharon Walmsley, Mark Halman, The Efavirenz Consensus Working Group

    Published 2001-01-01
    “…In routine practice, the discontinuation rate of efavirenz due to adverse effects appears higher than that described in clinical trials. To minimize early treatment interruption and maximize the benefit of long term viral suppression that can be achieved with efavirenz therapy, health care providers and patients have identified that there is a need for information, education about and practical tools for the management of efavirenz-related side effects. …”
    Get full text
    Article
  5. 2305

    The Effect of Hyperbaric Oxygen Therapy on Functional Impairments Caused by Ischemic Stroke by Emily R. Rosario, Stephanie E. Kaplan, Sepehr Khonsari, Garrett Vazquez, Niyant Solanki, Melanie Lane, Hiriam Brownell, Sheila S. Rosenberg

    Published 2018-01-01
    “…While research suggests a benefit of hyperbaric oxygen therapy (HBOT) for neurologic injury, controlled clinical trials have not been able to clearly define the benefits. …”
    Get full text
    Article
  6. 2306
  7. 2307

    A network-based analysis anticipates time to recovery from major depression revealing a plasticity by context interplay by Claudia Delli Colli, Aurelia Viglione, Silvia Poggini, Francesca Cirulli, Flavia Chiarotti, Alessandro Giuliani, Igor Branchi

    Published 2025-01-01
    “…We conducted a secondary analysis in two randomized clinical trials, STAR*D and CO-MED. Symptom severity was assessed using the Quick Inventory of Depressive Symptomatology while the context was measured at enrollment with the Quality-of-Life Enjoyment and Satisfaction Questionnaire. …”
    Get full text
    Article
  8. 2308

    Phytochemicals in Breast Cancer Prevention and Treatment: A Comprehensive Review by Adil Farooq Wali, Jayachithra Ramakrishna Pillai, Sirajunisa Talath, Pooja Shivappa, Sathvik Belagodu Sridhar, Mohamed El-Tanani, Imran Rashid Rangraze, Omnia Ibrahim Mohamed, Nowar Nizar Al Ani

    Published 2025-01-01
    “…Future research directions include refining these delivery approaches, further elucidating molecular mechanisms, and conducting clinical trials to validate findings. These efforts could significantly advance the role of phytocompounds in breast cancer management.…”
    Get full text
    Article
  9. 2309

    The Role of Oxidized Low-Density Lipoproteins in Atherosclerosis: The Myths and the Facts by Giuseppe Maiolino, Giacomo Rossitto, Paola Caielli, Valeria Bisogni, Gian Paolo Rossi, Lorenzo A. Calò

    Published 2013-01-01
    “…Finally, the results of randomized clinical trials employing antioxidants completed up to date, despite demonstrating no benefits in healthy populations, suggest a benefit in high-risk patients. …”
    Get full text
    Article
  10. 2310
  11. 2311

    Textural analysis and artificial intelligence as decision support tools in the diagnosis of multiple sclerosis – a systematic review by Filip Orzan, Ştefania D. Iancu, Laura Dioşan, Zoltán Bálint

    Published 2025-01-01
    “…Future research should prioritize clinical trials to establish the real-world applicability of AI-driven decision support tools. …”
    Get full text
    Article
  12. 2312

    The Relationship between Branched-Chain Amino Acid Related Metabolomic Signature and Insulin Resistance: A Systematic Review by Xue Zhao, Qing Han, Yujia Liu, Chenglin Sun, Xiaokun Gang, Guixia Wang

    Published 2016-01-01
    “…We performed systematic review, searching MEDLINE, EMASE, ClinicalTrials.gov, the Cochrane Library, and Web of Science from inception to March 2016. …”
    Get full text
    Article
  13. 2313

    Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy by Jan M. Keppel Hesselink, Ciro Costagliola, Josiane Fakhry, David J. Kopsky

    Published 2015-01-01
    “…PEA has been evaluated for glaucoma, diabetic retinopathy, and uveitis, pathological states based on chronic inflammation, respiratory disorders, and various pain syndromes in a number of clinical trials since the 70s of 20th century. PEA is available as a food supplement (PeaPure) and as diet food for medical purposes in Italy (Normast, PeaVera, and Visimast). …”
    Get full text
    Article
  14. 2314

    Employing the Oncolytic Vesicular Stomatitis Virus in Cancer Virotherapy: Resistance and Clinical Considerations by Alaa A. Abdelmageed, Stephen Dewhurst, Maureen C. Ferran

    Published 2024-12-01
    “…Several VSV-based phase I/II clinical trials show promise; however, addressing resistance and developing novel strategies to enhance therapeutic efficacy are essential for realizing the full potential of VSV oncolytic virotherapy. …”
    Get full text
    Article
  15. 2315

    CRISPR screen reveals modifiers of rAAV production including known rAAV infection genes playing an unexpected role in vector production by Emily E. O’Driscoll, Sakshi Arora, Jonathan F. Lang, Beverly L. Davidson, Ophir Shalem

    Published 2025-03-01
    “…Food and Drug Administration-approved AAV-mediated gene therapies already on the market and numerous more in clinical trials. However, manufacturing rAAV vectors is an expensive, timely, and labor-intensive process that limits the commercial use of AAV-mediated gene therapies. …”
    Get full text
    Article
  16. 2316

    The Efficacy and Mechanism of Chinese Herbal Medicine on Diabetic Kidney Disease by Zhenzhen Lu, Yifei Zhong, Wangyi Liu, Ling Xiang, Yueyi Deng

    Published 2019-01-01
    “…We will summarize the progress of Chinese herbal medicine (CHM) in the treatment of DKD from two aspects. In clinical trials, the Chinese herbal formulas were efficacy and safety confirmed by the randomized controlled trials. …”
    Get full text
    Article
  17. 2317
  18. 2318
  19. 2319

    The comparison of biodistribution of glutathione PEGylated nanoliposomal doxorubicin formulations prepared by pre‐insertion and post‐insertion methods for brain delivery in normal... by Amin Mehrabian, Saba Dadpour, Mohammad Mashreghi, Javad Zarqi, Anis Askarizadeh, Ali Badiee, Leila Arabi, Seyedeh Alia Moosavian, Mahmoud Reza Jaafari

    Published 2023-04-01
    “…Here, the 5% pre‐inserted PEG2000‐GSH PEGylated liposomal doxorubicin was conducted according to 2B3‐101 being tested in clinical trials. In addition, PEGylated nanoliposomal doxorubicin connected to the spacer‐GSH targeting ligand (GSGGCE) and the PEG3400 was conducted using post‐insertion method. …”
    Get full text
    Article
  20. 2320

    Global scenario of silica-associated diseases: A review on emerging pathophysiology of silicosis and potential therapeutic regimes by Prasad Sherekar, Sanvidhan G. Suke, Archana Dhok, Srikant Malegaonkar, Shrikrishna A. Dhale

    Published 2025-06-01
    “…The preclinical findings open the doors to clinical trials for operational and regenerative nanoformulations, which eventually create a positive change in medical practice. …”
    Get full text
    Article